|
Market Cap (5-Jul) $758,238,016 (475th) |
Close (30-Jun) $0.056 |
Volume (30-Jun) 1,984,515 |
Shortsold (19-Jun) 895,750 (0.15%) (396th) |
|
52w High $2.09 |
52w Low $0.90 |
P/E - |
EPS -0.11 |
PYC released this announcement to the ASX on 6 April 2021, 8:17. The announcement is not marked as price sensitive, and is 2 page(s) in length and 157.67kb in size.
You can view all announcements from PYC and see how they appear on a price chart on the announcements page.
At the date of this announcement, PYC was 0.000% short sold according to ASIC data. It was ranked the 610th most shorted stock on the ASX. It is now ranked as the 396th most shorted stock on the ASX with 0.154% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from PYC | |
|---|---|
| FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL | 30 June 2023, 8:17 |
| Change of Director's Interest Notice | 28 June 2023, 16:46 |
| PYC Investor Update Presentation | 16 June 2023, 8:32 |
| Quarterly Investor Call - 15th April 2021 | 6 April 2021, 8:17 |
| Appendix 3X - Initial Director's Interest Notice | 30 March 2021, 20:13 |
| Appendix 3G - Issue of Options | 30 March 2021, 20:12 |
| PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board | 29 March 2021, 10:54 |
You must be logged in to post a reply.
